On March 5, 2024 GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, reported that its abstract was selected for an oral presentation at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA (Press release, GV20 Therapeutics, MAR 5, 2024, View Source [SID1234640825]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the oral presentation are below:

Title: "IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target"
Session Type: Minisymposium
Session Category: Immunology
Session Title: Immune Targets and Therapies
Session Date/Time: Monday Apr 8, 2024, 2:30 PM – 4:30 PM
Abstract Presentation Number: 3914

More information can be found on the 2024 AACR (Free AACR Whitepaper) website.